Renal cell carcinoma with a novel RAB1A::ALK fusion: expanding the molecular spectrum of ALK-rearranged RCC.

Renal cell carcinoma associated with anaplastic lymphoma kinase rearrangement (ALK-RCC) is a rare subtype within the category of molecularly defined renal cell carcinomas. Due to its low incidence and highly heterogeneous clinicopathological features, ALK-RCC poses a significant diagnostic challenge. The implementation of advanced molecular techniques has facilitated the identification of various fusion partners, which may influence clinical behavior and guide targeted therapies. We report a case of ALK-RCC harboring a novel fusion partner, RAB1A::ALK. This report describes the clinicopathological and molecular features of the tumor, with a particular focus on the characterization of the RAB1A gene and its documented impact on carcinogenesis and prognosis across several solid malignancies. Our findings expand the molecular spectrum of ALK-RCC and emphasize the role of comprehensive molecular profiling in uropathology.